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Web interface–supported transmission risk assessment and
cost-effectiveness analysis of postdonation screening: a global
model applied to Ghana, Thailand, and the Netherlands_02351 2729..2742
Marinus van Hulst, Gijs A.A. Hubben, KwamenaW.C. Sagoe, Charupon Promwong,
Parichart Permpikul, Ladda Fongsatitkul, Diarmuid M. Glynn, Cees T. Smit Sibinga, and
Maarten J. Postma
BACKGROUND: The goal of our research was to
actively involve decision makers in the economic
assessment of screening strategies in their region. This
study attempted to accomplish this by providing an
easy-to-use Web interface at http://www.bloodsafety.info
that allows decision makers to adapt this model to local
conditions.
STUDY DESIGN AND METHODS: The cost-
effectiveness was compared of 1) adding antigen
screening to antibody screening for hepatitis C virus
(HCV) and human immunodeficiency virus (HIV); 2)
adding nucleic acid amplification testing (NAT) on hepa-
titis B virus (HBV), HCV, and HIV in minipool (pool of 6
[MP6] and 24 [MP24]) to antibody screening and hepa-
titis B surface antigen (HBsAg) screening; and 3)
individual-donation NAT on HBV, HCV, and HIV to anti-
body screening and HBsAg screening for Ghana, Thai-
land, and the Netherlands.
RESULTS: The combination of HCV antibody-antigen
combination (combo) and HIV combo added to antibody
screening in Ghana and Thailand was cost-effective
according to the WHO criteria. MP24-NAT screening in
Ghana was also cost-effective. MP24-NAT on HBV,
HCV, and HIV was not cost-effective compared to the
other screening strategies evaluated for the Nether-
lands. Large regional differences in cost-effectiveness
were found for Thailand.
CONCLUSION: The young transfusion recipient popula-
tion of Ghana in combination with a high risk of viral
transmission yields better cost-effectiveness for addi-
tional tests. The advanced age of the transfused popu-
lation of the Netherlands and a small risk of viral
transmission gives poor cost-effectiveness for more
sensitive screening techniques. It was demonstrated
that a global health economic model combined with a
Web interface can provide easy access to risk assess-
ment and cost-effectiveness analysis.
E
conomic evaluations of interventions to
enhance blood transfusion safety have appeared
since the 1980s andmainly concern blood donor
screening.1,2 The type of analysis underlying
such economic evaluation generally employs mathemati-
cal modeling to simulate the health consequences and
associated costs of transfusion-transmitted infections.
ABBREVIATIONS: ART = antiretroviral therapy; CER(s) = cost-
effectiveness ratio(s); combo = antibody-antigen combination;
DALY(s) = disability-adjusted life-year(s); GNI = Gross National
Income; ICER = incremental cost-effectiveness ratio;
ID = individual donation; MP(s) = minipool(s); MP6 = minipools
of 6; MP24 = minipools of 24.
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The local conditions of a region strongly determine the
outcome of such amodel. Themost appropriate screening
strategy will depend on factors such as the incidence
of infections in the donor population, the resources
available to allocate to screening, and the health care
infrastructure.
Therefore, for thesemodels to play a useful role in the
decision-making process, they must be adapted to local
conditions. However, up-to-date regional data are often
only available to local decisionmakers and the exact infor-
mation requirements of these decision makers are fre-
quently unknown.
The goal of our research is to actively involve medical
professionals and decision makers in the economic
assessment of blood donor screening strategies in their
region. We attempt to accomplish this by providing an
easy-to-use Web interface that allows users to adapt our
global model to local conditions and perform customized
transmission risk assessments and cost-effectiveness
analyses of several postdonation blood donor screening
strategies.
In this article, we present the results of this model
applied to Ghana, Thailand, and the Netherlands, using
the Web interface that we developed for this health-
economic model.We have chosen these countries to illus-
trate the potential impacts of large difference in local
conditions and corresponding model outcomes between
a typical developing, transitional, and developed country.
Incident rates for hepatitis B virus (HBV), hepatitis C virus
(HCV), and human immunodeficiency virus (HIV) in
blood donors are high in Ghana, intermediate inThailand,
and relatively low in the Netherlands.3-6 Also, the popula-
tion of blood transfusion recipients in Ghana, as an
example for sub-Saharan Africa, is on average much
younger than blood transfusion recipients in the devel-
oped world.7 Young patients with malaria and iron
deficiency–related pediatric anemia represent a large
share in the patient population. In contrast, in the devel-
oped world more than 50% of the units are transfused to
patients aged 65 and older.8,9
Antibody screening is universally and widely applied
in many countries. The residual viral transmission after
antibody screening for HCV and HIV and screening for
hepatitis B surface antigen (HBsAg) can be further
reduced by adding more sensitive tests. For instance,
antigen screening or nucleic acid amplification testing
(NAT) reduces the time between the development of
infectious viremia and the possible detection (i.e., the
window period) and thus lower the residual transmission
risk.10 The objective of our study and theWeb interface is
to weigh the extra costs of adding more advanced screen-
ing techniques against savings in reduced health care
costs for HBV, HCV, and HIV and corresponding health
gains in these infections being averted. The approach is
illustrated by performing incremental cost-effectiveness
analyses of adding additional testing to existing screening
strategies:
1. Adding antigen screening to antibody screening for
HCV11 and HIV (HCV antibody [Ab] and HIV-Ab);
2. Adding NAT to HCV-Ab and HIV-Ab screening; and
3. Adding NAT to antigen testing for HBV (HBsAg).
NAT can be evaluated in minipools (MPs) with
various pool sizes or on each individual donation (ID).
Both options are investigated below.
As is common in health-economic research, we
explicitly distinguish the base case analysis from sensitiv-
ity and scenario analyses. All results of the base case and
additional analyses presented below were calculated
using the Web interface that is publicly accessible at
http://www.bloodsafety.info. In the discussion, we will
further address the potential role thatWeb-based interac-
tion with health-economic models could play in support-
ing future decision making.
MATERIALS AND METHODS
Model overview
Cost-effectiveness of transfusion safety was simulated for
Ghana, the Netherlands, and Thailand in a cohort of
10,000 donations to 1) illustrate the use of aWeb interface
to perform an economic evaluation and 2) to actually
provide up-to-date estimates of cost-effectiveness of
enhanced screening methods for blood transfusion safety
in these three countries. In the base case the residual risk
of transmission and the cost of screening were estimated
for five postdonation screening strategies:
1. HBsAg, HCV-Ab, and HIV-Ab;
2. HBsAg, HCV-Ab + Ag (HCV combo), and HIV-
Ab + Ag/p24 (HIV combo);
3. MP24-NAT (pool of 24 donations on HBV, HCV, and
HIV) + HIV-Ab, HCV-Ab, and HBsAg;
4. MP6-NAT (pool of 6 donations on HBV, HCV, and
HIV) + HIV-Ab, HCV-Ab, and HBsAg; and
5. ID-NAT (on HBV, HCV, and HIV) + HIV-Ab, HCV-Ab,
and HBsAg.
From the estimated HBV, HCV, and HIV transmission
risks the number of infected transfusion recipients was
estimated using country-specific processing characteris-
tics for donation, regarding the whole process from the
donor to the patient. The burden of disease and arising
treatment cost as a result of transfusion-acquired infec-
tions was modeled in country-specific patient cohorts. All
costs were expressed in US$ (2006 price levels).
Using theWeb interface, the user can change the vari-
ables of several predefined scenarios that we describe in
this article: one for developing countries in Africa (in this
case Ghana), one for transitional countries in Asia (three
regions inThailand), and one for the developed world (the
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Netherlands). To compare transmission risks and cost-
effectiveness of two screening strategies, the user selects
the appropriate comparison, chooses the scenario that
resembles the region of interest most, optionally adapts
variables, and performs the simulation (Fig. 1).
Donation; screening; and residual risk of HBV,
HCV, and HIV transmission
Data on donations and subsequent processing for Ghana
were obtained during 2004 from theNational BloodTrans-
fusion Service located at the Korle Bu Teaching Hospital
(Accra, Ghana). Data on donating and processing forThai-
land were retrieved from the information systems of the
blood banks of the Prince Songkla University (Songkla,
Thailand) and the Siriraj Hospital (Bangkok, Thailand).
For the Netherlands data on donating and processing was
obtained from the 2006 annual report of the Sanquin
Blood Supply Foundation and a cost-effectiveness analy-
sis of pathogen inactivation that was previously per-
formed5,12 (see Table 1 for the input variables for the base
case).
In theWeb interface the user has two options to esti-
mate the residual transmission risk of a screening strategy.
The preferred method is the incidence window period
model, which is to be used if the incidence is known.13,14 In
the incidence window period model the residual risk of
infection after testing is estimated by multiplying the
window period (Table 2) for the particular test with the
incidence of the infection (Table 1).14-16 This method can
certainly be used for the Netherlands. However, most
blood banks in middle human development index (for
example, Thailand) and low human development index
(for example, Ghana) countries rely (in part) on one-time
replacement donors to provide an adequate blood supply.
Prevalence estimates can be obtained, but incidence rates
are not readily available for these countries because these
replacement donors are not followed up.17 In these cir-
cumstances the detuned assay is an option to estimate the
incidence; however, this is yet seldom available.18 If the
incidence is not known, the user can estimate the residual
risks of transmissions with an adapted version of the
window periodmodel using the prevalence (see Appendix
A, available as supporting information in the online
version of this paper). The adapted version of the window
period model is also used for the risk of transmission by
first-time donors.
As HBV infection resolves, HBsAg titers decline to
undetectable levels that can yet still be detected by
ID-NAT.19 The incidence of HBsAg positivity in repeat
Fig. 1. Selecting the assays to be compared for the transmission risk assessment and cost-effectiveness analysis. Users can also cus-
tomize available scenarios to their local situation.
WEB INTERFACE–SUPPORTED DECISION MAKING
Volume 49, December 2009 TRANSFUSION 2731
donors therefore underestimates the incidence of HBV
infection. As a transientmarker of infection, HBsAg can be
cleared before the follow-up donation. In the incidence-
based transmission risk estimation a correction factor was
used to compensate for the transient nature of HBsAg.The
incidence of HBsAg positivity is multiplied by a correction
factor, 2.38 for Thailand and Ghana20 and 3 for the
Netherlands.5 In the prevalence-based transmission risk
estimation an extra window period was included for
late-stage HBV infection.
Country-specific incidence; prevalence; estimated
transmission risks for HBV, HCV, and HIV; and costs are
presented in Table 1. The screening costs were estimated
by multiplying the country-specific cost of the screening
strategies with the number of donations in the cohort.
Currently, only the costs of the tests and the reagents are
included since labor costs, training costs, and amortized
costs of equipment were not available.
Patient population; HBV, HCV, and HIV infections;
and costs
Data on the clinical use of blood transfusion and the blood
transfusion recipient were collected for each of the
included countries. Because costs and outcomes of
transfusion-acquired infectious diseases vary with age,
the exact age of recipients is important and the mean age
of the transfused patient for each of the included coun-
tries was specifically estimated (Table 3). Also, the risk of
receiving an infected unit was calculated from the blood
transfusion utilization and the number of blood products
processed from one donation for each country. Hospital
mortality due to causes unrelated to transfusion was esti-
mated at 6.89% for Ghana. Hospital mortality included
patients dying during admission. Long-term excess mor-
tality of blood transfusion recipients was not included
in the model for Ghana and Thailand since it is only
described for the developed world, where patients trans-
fused are older and suffer from different underlying dis-
eases.8,21,22 For the Netherlands long-term excessmortality
was estimated at 20% at 1 year posttransfusion.8
Health consequences of HBV and HCV infection were
modeled with previously reported Markov models.23-25 In
2003, vaccination for HBV started in Ghana and 85% of
transfused patients born after 2003 were assumed to be
vaccinated.26 The effectiveness of the HBV vaccine was
assumed to be 98%.27,28 The susceptibility toHBV infection
in patients not vaccinated against HBV was modeled at
20% for patients aged more than 10 years and 70% for
those aged less than 10 years.29 The susceptibility to HBV
for the average patient was estimated at 20%. The treat-
ment costs for cirrhosis and hepatocellular carcinoma
TABLE 1. Variable estimates for blood donation and screening
Model variable
Base case values
Ghana Thailand The Netherlands
Blood donation
Number of donations per transfusion 1.07 1.66 1.66
Viral marker screening Prevalence (%) Prevalence (%) Incidence (per 1 ¥ 106 donor years)
HBsAg 15 2.51
B1.20;C4.71;S1.61
11
Anti-HCV 4 0.72
B0.50;C1.31;S0.36
2.6
Anti-HIV 2.49 0.39
B0.20;C0.81;S0.16
5.5
Cost of screening (US$/donation)
HIV Ab 0.6 0.6 0.8
HIV combo (Ab, p24) 0.8 0.8 0.9
HIV MP24-NAT + HIV Ab 6.6 6.6 10.8
HIV MP6-NAT + HIV Ab 9.2 9.2 10.9
HIV ID-NAT + HIV Ab 17.4 17.4 20.8
HBsAg 0.4 0.4 0.5
HBV MP24-NAT + HBV Ab 6.4 6.4 10.5
HBV MP6-NAT + HBV Ab 9 9 10.8
HBV ID-NAT + HBV Ab 17.2 17.2 20.5
HCV Ab 2.6 2.6 4
HCV combo (Ab, p24) 4.0 4.0 5
HCV MP24-NAT + HCV Ab 8.6 8.6 14.0
HCV MP6-NAT + HCV Ab 11.2 11.2 14.3
HCV ID-NAT + HCV Ab 19.4 19.4 24.0
Multiplex MP24-NAT + HIV Ab, HBsAg, HCV Ab 9.6 9.6 15.3
Multiplex MP6-NAT + HIV Ab, HBsAg, HCV Ab 12.2 12.2 15.6
Multiplex ID-NAT + HIV Ab, HBsAg, HCV Ab 20.4 20.4 25.3
All costs in 2006 US$.
Ab = antibody; Ag = antigen; B = Bangkok; C = Chiang Mai; S = Songkla.
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were included in the model for HBV and HCV and were
obtained from the Korle Bu Teaching Hospital (Accra,
Ghana). In Thailand, universal vaccination of newborn
infants for HBVwas introduced in 1992.30Vaccination cov-
erage reached 92% in 1995 and has remained more than
95% ever since.31 Currently, 33% of the blood transfusion
recipients are assumed to be still susceptible to HBV
infection.30 Treatment costs associated with HBV andHCV
disease states were obtained from diagnosis-related
group costs from the Prince Songkla University Hospital
(Table 3). Since March 2003, 15% of all newborns belong-
ing to high-risk groups in the Netherlands have received
vaccination for HBV.32 Approximately 4% of the Dutch
population aged between 40 and 75 years were estimated
to be carriers of anti-HBc in 1995.33 The susceptibility of
Dutch blood transfusion recipients was accordingly
assumed at 95%. In the absence of Dutch data, costs of
treatment associated with HBV and HCV were derived
from German cost data.34,35 HBV transmission from
donors with occult HBV infection was not included in
this evaluation.
HIV infection was simulated using a two-stage
Markov model.36 Patients from Ghana were assumed to
progress faster to the AIDS stage compared to patients
from Thailand and the Netherlands. These progression
rates are actually confined to the predefined scenarios in
the Web interface, the user cannot change this. To model
the extension of the HIV stage and longevity by antiretro-
viral therapy (ART), it was assumed that antiviral drugs
would be available for 7.5% of the patients in the base
case, representing the current situation in Ghana.37,38 All
infected patients were assumed to receive standard care
for sequelae of HIV infection. ART was assumed to be ini-
tiated at HIV WHO Stage 3 (clinical symptoms and CD4
count of <200 ¥ 106 cells/L), continued life-long and esti-
mated to yield an additional 12 life-years in the base
case.39-42 The accessibility to ART for Thai transfusion
recipients was assumed at 60%.43 In the Netherlands all
patients contracting HIV from blood transfusion were
assumed to receive ART. Annual costs of ART and standard
care for HIV patients are displayed in Table 3.
As a measure of burden of disease, the disability-
adjusted life-year (DALY) was estimated by adding the
years of life lost and the adjusted years lived with disease.
The years of life lost per patient from transfusion-acquired
infections were determined as the difference between the
patient-specific life expectancy and the life expectancy
after HBV, HCV, or HIV infection. The life expectancy after
HBV, HCV, or HIV infection was estimated from the
respective Markov models described in the preceding
section. Country- and age-specific remaining life expect-
ancies were taken from the WHO and directly applied to
patients receiving blood transfusions.44 Years lived with
disease was reflected by the total time per patient in the
HBV, HCV, HIV disease states multiplied by the appropri-
ate disability weight.45
Cost-effectiveness
The cost-effectiveness of the screening strategies was
evaluated from the health care perspective. We estimated
the cost-effectiveness ratio (CER), that is, the costs divided
by the additional health gains of a screening strategy
(intervention), compared with doing nothing. Addition-
ally, we estimated the incremental cost-effectiveness ratio
(ICER), that is, the additional costs of a screening strategy
divided by the additional health gains of a screening strat-
egy, compared with the next least expensive screening
strategy (comparator). Figure 2 illustrates these compari-
sons. Screening strategies that cost more and result in less
health gains than other screening strategies were excluded
(dominated). Next to dominated strategies, we labeled
“extended dominated” alternatives. Extended dominated
strategies are those strategies for which we can find
another strategy that is more costly and provides more
health gains, but at a more favorable (lower) CER.
The estimated (I)CERs were compared with the per-
capita Gross National Income (GNI) of the respective
countries. According to WHO guidelines, strategies that
show a (I)CER below the per-capita GNI are regarded as
cost-effective, whereas strategies with a (I)CER above
TABLE 2. Transmission risk estimation: window
period of screening strategies and incubation
time
Screening strategy
Window period
(days)
HIV Ab14 20.3
HIV combo (Ab, p24)14 15
HIV MP24-NAT + HIV Ab14 9
HIV MP6-NAT + HIV Ab15 7.4
HIV ID-NAT + HIV Ab14 5.6
HBsAg16 38.3
Late-stage HBsAg19 24.0
HBV MP24-NAT* + HBsAg16 38.3
Late-stage HBV MP24-NAT + HBsAg19 24.0
HBV MP6-NAT + HBsAg15 22.6
Late-stage HBV MP6-NAT + HBsAg15,19 14.1
HBV ID-NAT + HBsAg15,16 20.6
Late-stage HBV ID-NAT + HBsAg15,19 12.9
Incidence correction factor for transient
HBsAg infection in repeat donors20
2.38
(Netherlands 35)
HCV Ab14 58.3
HCV combo (Ab, Ag)14 12.5
HCV MP24-NAT + HCV Ab14 7.4
HCV MP6-NAT + HCV Ab14 6.1
HCV ID-NAT + HCV Ab14 4.9
Duration of disease stages without apparent
clinical signs, i.e., incubation time (year)
HIV (WHO Stages 1 and 2) 5
HBV 22
HCV 22
* No difference in window period between HBsAg and MP24-
NAT.
Ab = antibody; Ag = antigen.
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three times the per-capita GNI are regarded as not cost-
effective.46,47 The health gains were expressed as DALYs
averted, that is, the reduction in premature death and
morbidity due to averted transfusion-transmitted infec-
tions by the specific screening strategy. The DALYs associ-
ated with each screening strategy were determined by
multiplying the residual risk of HBV, HCV, or HIV trans-
mission for the specific screening strategy with the DALYs
caused by transfusion-acquired diseases. In line with
health-economic guidelines (http://www.ispor.org),
DALYs were discounted at 3% and weighted for age in the
base case; an evaluation without age weighing was also
performed.45 The costs per screening strategy were esti-
mated by adding the costs of screening and health care
costs of transfusion-acquired infections. Future costs were
also discounted at 3% annually.
Using the Web interface the user
can evaluate combinations of 19 screen-
ing strategies (of which five are
described is this article) in three coun-
tries. It contains more than 80 model
variables that can be changed. Within
the limited space of an article we
present only the sensitivity of the out-
comes to test costs; mean age of the
blood transfusion recipient; incidence (or prevalence) of
the viral markers in donors; and treatment costs for HBV,
HCV, and HIV.
RESULTS
Base case analysis
HCV antigen screening prevented more transfusion-
transmitted infections than HIV p24 antigen screening,
both in addition to antibody screening. Ghana was the
country with the greatest number of cases prevented by
adding antigen screening for HIV and HCV to antibody
screening (Table 4). Ghana also had the highest prevented
disease burden (inDALYs) by additional antigen screening
for HIV and HCV. HIV antigen screening contributed
to 82% of the prevented disease burden in this region.
TABLE 3. Key variable estimates for patients receiving a blood transfusion*
Model variable
Base case values
Ghana Thailand The Netherlands
Epidemiology
Mean age (year) 237 45.46 65
Hospital mortality (%) 6.89 0 0
First-year mortality (%) 0 0 20
Number of secondary HIV transmissions (R0) 1 1 0
HIV
Recipients infected with HIV before transfusion (%) 2.357 1.458 0.259
HIV progression model36 Fast Slow Slow
Accessibility to ART (%) 7.537,38 6058 10059
Duration of WHO Stages 1 and 2 (year) 5 5 5
Extension of WHO Stage 3 by ART (year) 12 12 12
Disability weight HIV45 0.136 0.136 0.136
Disability weight AIDS45 0.505 0.505 0.505
Cost of basic care for PLWHA (US$/year) 35 35 12,500
Cost of ART for WHO Stages 3 and 4 (US$/year) 380 1,158 12,500
HBV
Recipient susceptibility to HBV infection (%) 20 33 95
Progression to chronic hepatitis (%) 5 5 5
HCV
Recipients infected with HCV before transfusion (%) 4 4.860 0
Spontaneous remission (%) 31 31 31
HBV and HCV
Access to liver transplantation (%) 0 0 100
Disability weight cirrhosis 0.18 0.18 0.18
Disability weight decompensated cirrhosis 0.49 0.49 0.49
Disability weight HCC 0.45 0.45 0.45
Cost of cirrhosis (US$/year) 485 310.82 918
Cost of decompensated cirrhosis (US$/year) 485 13,973.10 17,091
Cost of HCC (US$/year) 360 6760.11 22,514
Cost of liver transplantation (US$ in the first year) NA NA 159,952
* All costs in 2006 US$.
HCC = hepatocellular carcinoma; NA = not applicable; PLWHA = persons living with HIV or AIDS.
Fig. 2. Calculation of the CER.
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Compared to Ghana, the disease burden prevented by
adding antigen screening for HIV and HCV was lower for
Thailand.HIV contributed to 72%of the prevented disease
burden by additional antigen screening in Thailand. The
prevented disease burden and the number of cases of HIV
and HCV prevented by additional antigen screening was
the lowest for the Netherlands. In contrast to the disease
burden, the difference in the total costs between the
combo tests for HIV and HCV and the HIV and HCV anti-
body screening strategy was similar among the different
countries. Prevented treatment costs contributed to a
small share of the difference in costs between combo and
antibody screening; only 18.9%, 6.3%, and a negligible
percentagewere found forThailand, Ghana, and theNeth-
erlands, respectively. The CER of combo tests for HIV and
HCV compared to the respective antibody tests was con-
sistently lower than the other evaluated screening strate-
gies. For Ghana, this CER was below the three times GNI
threshold of cost-effectiveness. Adding antigen testing to
antibody screening in the Netherlands is expected to yield
a CER more than three times the GNI. In Thailand large
regional differences were seen. In Chiang Mai the CER for
HIV and HCV combo assays was below the GNI threshold
of cost-effectiveness. For the whole of Thailand, the CER
for using HIV and HCV combo assays instead of anti-
body assays was below the three times GNI per-capita
threshold.
MP24-NAT prevented less disease burden in addition
to HCV and HIV combo at higher costs than HCV and HIV
combo relative to antibody screening. Therefore, the cost-
effectiveness of MP24-NAT is lower (higher costs-to-
benefit ratio, CER) than for HIV and combo screening
(lower CER). The greatest number of infections and
disease burdenwas prevented in Ghana, followed byThai-
land. The number of HBV, HCV, and HIV infections pre-
vented was very low for the Netherlands. Of the evaluated
countries, Ghana displayed the lowest (most favorable)
CER for MP24-NAT screening relative to combo tests
which was just below the three times the GNI per capita of
cost-effectiveness. Thailand and the Netherlands showed
CERs more than four and 1600 times the per-capita GNI.
In line with the previous observations, the more sen-
sitive and more expensive MP6-NAT screening strategy
gave less health benefit compared to the next least expen-
sive strategy (MP24-NAT) and thus higher costs-to-benefit
ratios (CERs), except for the Netherlands. The small dif-
ference in expected test costs between MP24-NAT and
MP6-NAT together with more transfusion-infected cases
prevented resulted in relatively low costs-to-benefit ratio
for MP6-NAT screening. The reduction of disease burden
in Thailand and the Netherlands can for the larger part be
attributed to the prevention of HBV transmission. The
CER was more than three times GNI for all evaluated
countries. ID-NAT added to antibody screening gave the
highest ratio of the CER to the GNI.
Figure 3 shows that for Ghana and Thailand all
evaluated screening strategies are on the cost-
effectiveness frontier. None of the evaluated strategies
were more effective and less costly than another screen-
ing strategy for these countries. When ordered from least
effective to most effective, as in Fig. 3, the estimated CERs
resembled the ICERs because none of the strategies can
be eliminated in the evaluations for Ghana and Thailand.
With the given variables and assumptions, the disease
burden prevented and costs associated with MP24-NAT
screening added to antibody screening for the Nether-
lands are below the line that connects combo tests to
MP6-NAT added to antibody screening. The CER of
MP24-NAT relative to combo tests is higher than the CER
of MP6-NAT relative to combo tests. In this case, MP24-
NAT added to antibody screening is eliminated and only
antibody screening, combo tests, MP6-NAT, and ID-NAT
must be considered. The ICER of ID-NAT versus MP6-
NAT was US$60.5 million per DALY prevented which is
more than 1600 times higher than the GNI per capita for
the Netherlands. At US$7.6 million per DALY prevented,
the ICER of MP6-NAT versus HCV and HIV combo test is
considerably lower.
Conventional sensitivity analysis
Figure 4 shows the sensitivity of the CER to changes in test
costs; mean age of the blood transfusion recipient; the
incidence rates (or prevalence) of viral markers in blood
donors; and treatment costs for HBV, HCV, and HIV. The
CER is very sensitive to changes in test costs. In particular,
comparisons of antibody and combo tests are very sensi-
tive to changes in costs because of the small difference in
costs between both screening methods. A test cost reduc-
tion of 25% yielded a 65% to more than 90% lower (more
favorable) CER. Reducing the costs of MP24-NAT in com-
bination with antibody screening by 25% lowered the CER
ofMP24-NAT relative to combo tests below the three times
GNI per-capita threshold Thailand. The cost-effectiveness
of screening strategies is sensitive to changes in the preva-
lence or incidence of transfusion-transmissible infection
in donors. In particular, the expected costs and benefits of
MP6-NAT compared to MP24-NAT are very sensitive to
the estimation of theHBV transmission risk. The influence
of themean age of the blood transfusion recipient was the
greatest for the Netherlands. Changes in treatment costs
for HBV, HCV, and HIV were of little consequence for all
countries and screening strategies included (data not
shown). However, projecting future improvement of treat-
ment options for Thailand negatively impacted the cost-
effectiveness of screening strategies. An expected 100%
access to ART combined with a higher survival (an
extended survival of 24 instead of 12 life-years) and 100%
access to liver transplantation increased the CER more
than twofold for MP-NAT versus combo tests. This was
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mainly caused by the reduction in disease burden caused
by HIV, HCV, and HBV.
DISCUSSION
We investigated the cost-effectiveness of screening blood
donations for HBV, HCV, and HIV in Ghana, Thailand, and
the Netherlands using a Web interface to a global model
comprising country and patient population–specific sur-
vival, blood product utilization, and direct cost data. We
found that adding tests to HBsAg and antibody screening
for HIV and HCV would prevent the most disease burden
in Ghana, followed by Thailand, and finally the Nether-
lands. Given the variables and underlying assumptions of
our model, introducing HIV and HCV combo tests instead
of antibody screening was estimated to be cost-effective
for Ghana and Chiang Mai (Thailand). In both scenarios
the base case ICER was below the three times GNI per-
capita threshold that has been suggested by both theWHO
and the World Bank for very cost-effective interventions.
The averted disease burden could mainly be attributed to
prevention of HIV transmission. ID-NAT was not cost-
effective in any of the explored scenarios. For all evaluated
regions the ICERs of ID-NAT relative to the next least
expensive screening strategy were well over three times
the GNI per-capita threshold for cost-effectiveness over
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ICER = 608 US$ / DALY 
ICER = 1,154 US$ / DALY 
ICER = 5,301 US$ / DALY 
Ghana
ICER = 18,836 US$ / DALY 
Thailand 
ICER = 12,930 US$ / DALY 
ICER = 5,765 US$ / DALY 
ICER = 5.8 million US$ / DALY 
ICER = 7.6 million US$ / DALY 
The Netherlands Bangkok — , Chiang Mai ·······, Songkla −−−−
ICER = 2,468 US$ / DALY 
ICER = 47,834 US$ / DALY 
ICER = 60.5 million US$ / DALY 
Fig. 3. Prevented disease burden (DALYs) and total costs of postdonation screening per 10,000 donations in Ghana, Thailand, the
Netherlands, and regional scenarios for Thailand (Bangkok, Chiang Mai, and Songkla). Strategies on the right of the line are domi-
nated by the strategies on the line because these strategies are less effective or cost more than the strategies on the line. This line
also represents the ICER. ICER estimates are not shown for the regional scenarios for Thailand (Bangkok, Chiang Mai, and
Songkla). All costs in 2006 US$. () antibody; ( ) combo = antibody + antigen; (*) MP24-NAT; () MP6-NAT; (H17009) ID-NAT.
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which interventions are regarded not cost-effective.
MP24-NAT was cost-effective for Ghana, Bangkok (Thai-
land), and Chiang Mai (Thailand) because in these sce-
narios the ICER was one to three times the GNI per capita.
Interestingly, for the Netherlands, MP24-NAT added to
antibody screeningwas dominated by a screening strategy
comprising HIV and HCV combo tests and also by MP6-
NAT added to antibody tests. MP48-NAT for HIV and HCV
in combination with HBsAg and antibody screening for
HIV and HCV is the current screening strategy in the
Netherlands. In Thailand blood donations are generally
screened for HBsAg and antibodies to HIV andHCV. Some
blood centers in Thailand are currently implementing
ID-NAT for HBV, HCV, and HIV in combination with serol-
ogy. In Ghana blood donations are mainly screened for
HBsAg and antibodies to HIV and HCV.
Health care interventions in sub-Saharan Africa tar-
geted at communicable diseases are associated with CERs
0% 50% 100% 150% 200% 250%
ID-NAT vs MP6-NAT
MP6-NAT vs MP24-NAT
MP24-NAT vs Combo
Combo vs HIV, HCV Ab, HBsAg
The Netherlands
Thailand
Ghana
The Netherlands
Thailand
Ghana
The Netherlands
Thailand
Ghana
ID-NAT vs MP6-NAT
MP6-NAT vs MP24-NAT
The Netherlands
Thailand
Ghana
The Netherlands
Thailand
Ghana
Percentage of the cost-effectiveness ratio relative to the base case 
Combo vs HIV Ab, HCV Ab, HBsAg (costs Combo -25% to+25% ) 
MP24-NAT vs Combo (costs MP-NAT -25% to + 25%)  
Thailand (HBV incidence 25% of base casea)
ID-NAT vs MP-NAT (costs NAT -25% to +25%) 
ID-NAT vs MP-NAT (mean age -5 to +5 years) 
MP-NAT vs combo (incidence or prevalence +25% to -25%) 
Thailand (without treatment costs and with best possible treatmentb)
Fig. 4. Sensitivity analysis of selected variables. Antigen (Ag; combo) and NAT were in addition to HBsAg, HCV antibody (Ab), and
HIV Ab. aMP24-NAT versus HBsAg is not evaluated because the window periods are the same;16 bpossible treatment comprises 100%
access to ART for HIV with a duration of effect of 24 years and 100% access to liver transplantation.
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ranging fromUS$121 perDALY averted formalaria control
and US$310 per DALY averted for prevention of mother-
to-child HIV transmission up to US$542 to $1280 per
DALY averted or US$1180 per life-year gained for provid-
ing highly active ART.48-50 Expanding blood donations
screening with HIV-antigen tests does not compare favor-
ably with these specific interventions. Compared to CERs
for expandingHIV screening in themore developedworld,
which easily exceed US$1 million per DALY averted
(I)CERs found for introducing additional screening in
Ghana and Thailand represent much greater value. The
rank order in the value formoney is mainly determined by
two variables: 1) the risk of viral transmission and 2) the
mean age of the transfusion recipient. Due to the incuba-
tion time of HBV, HCV, and HIV, the younger transfusion
recipient population in Ghana will experience more
disease burden than the older transfusion recipient popu-
lation of the Netherlands. Obviously, the much higher risk
of viral transmission in Ghana relative to the Netherlands
will provide better cost-effectiveness for more sensitive
screening strategies.
One limitation of our evaluation is the determination
of the residual risk of viral transmission by using the
prevalence instead of the preferred incidence window-
phase approach or the application of a detuned assay.13,51
However, our estimated residual risk may be a good
approximation, since the risk of 2.76 per 10,000 donated
units after HIV antibody screening in the present study
falls well within the range from a previously reported
direct determination. In this study, performed in Kumasi
(Ghana) with a comparable HIV prevalence, 0.6 to 3.9
infective units per 10,000 donated units were found.52 Also
transmission risks estimated for HIV, HCV, and HBV infec-
tion inThailand, 1:80,000, 1:230,000, and 1:9600 per dona-
tion, respectively, compare reasonably well to a recent
study conducted in Thailand. In this study the combined
ID-NAT/MP6-NAT yield rates for HIV, HCV, and HBV were
1:97,000, 1:490,000, and 1:2800 per donation, respec-
tively.53 As was shown by our analysis, the estimation of
HBV transmission risk is critical for taking an informed
decision to adopt either MP6-NAT or MP24-NAT screen-
ing in Thailand. A further limitation of this evaluation is
that only window period HIV transmissions are consid-
ered, disregarding transmissions due to technical or
human failure, which could also potentially be reduced by
additional screening tests.54 At first glance, users can only
use the mean age of the transfused population. This cer-
tainly has drawbacks since the course of infection with
HBV, HCV, and HIV is age dependent. However, the
disease models accessed from the Web interface are age
dependent. Therefore, more experienced users can esti-
mate the cost-effectiveness based on an age distribution
of the transfused population by performing evaluations
for each age group in that specific population. Labor costs,
training costs, and amortized costs of equipment were not
included in the screening costs. This is a potential favor-
able bias toward labor and capital intensive screening
strategies, such as NAT. The estimation of labor costs,
training costs, and amortized costs of equipment is left for
further work.
We note several problems regarding the usability of
economic studies on blood transfusion screening strate-
gies to support decision making. For model developers,
local data for the many regions a model could theoreti-
cally be applied to is frequently unavailable. Moreover, the
number of possible screening strategies is very large and
the exact information requirements of decision makers
are very difficult to anticipate. As science progresses and
new evidence comes available, economic studies need to
be updated, but such updates are rarely reported in litera-
ture. When updates appear, it is mainly as letters, and no
complete overview is provided.55,56
We believe that a solution to these problems lies in
the development of global economic models that are
transferable to many regions. Local researchers, medical
professionals, and decisionmakers could bemore actively
involved in applying these models to their own settings.
This approach could 1) lower the barrier of entry to eco-
nomic evaluation, 2) advocate cost-effectiveness analysis
to support policy decisions, and 3) increase the transpar-
ency of economic studies.
Particularly in regions with limited resources, where
explicit trade-offs are necessary, cost-effectiveness analy-
sis can contribute to a more optimal allocation of health-
care resources. However, these regions often lack the
financial resources to develop their own models. Our
approach can lower the barrier to perform cost-
effectiveness analysis and at the same time raise aware-
ness of the usefulness of such analysis and provide
background information on the method used.
To allow interaction with economic models, we
believe that a Web interface offers several significant
advantages. It avoids the need for nonexperts to interact
with complex modeling technology directly. Additionally,
it is an efficient way of distributing a model to a globally
distributed audience. Finally, a Web-based system allows
multiple users to share model data and this opens up
new opportunities for remote communication and
collaboration.
Directions of future research
We recommend the formation of an expert panel of health
economists to guide and support local decision makers
and researchers with the collection of reliable local data
required for a correct assessment for their region. TheWeb
interface can be further developed into a more advanced
communication platform to support the dialogue and
exchange of knowledge between an expert panel and local
decision makers and researchers. Ideally, this platform
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should allow the broader blood bank community to share
regional scenario data and correspondingmodel outcome
and benefit from each other’s work.
This initiative was recently adopted by the subgroup
on cost-utility analysis and risk assessment of the Interna-
tional Society Blood Transfusion working party on
transfusion-transmitted infectious diseases and will be
further developed within that framework.
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